UA129502U - METHOD OF FORECASTING OSTEOARTHrosis DEVELOPMENT - Google Patents

Abstract

A method for predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the serum of the patient determine the polymorphism of genes methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of oxyproline, homocysteine, C-reactive protein (PSA). When homozygous carrier 677-TT, 786-SS and oxyproline levels> 15 μmol / l, homocysteine> 20 μmol / l, PSA> 6 mg / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology, and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK) is determined in the patient's blood serum

C677T), nitric oxide synthase (EeMO5 T786C), content of oxyproline, homocysteine, C-reactive protein (CRP). With homozygous carrier 677-TT, 786-SS, levels of oxyproline 215 μmol/l, homocysteine 220 μmol/l, SRP »6 mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are performed, the polymorphism of MTNEK C677tT, eMmo5 T786C genes is determined, the content of oxyproline, homocysteine, SRP is determined by the immunoenzymatic method. With homozygous carriers of 677-HT, 786-SS, levels of oxyproline 215 μmol/l, homocysteine 220 μmol/l, SRP »b mg/l predict the development of osteoarthritis.

A specific example of using the method.

Patient K., 55 years old, was hospitalized in the clinic due to pain syndrome in the right knee joint. X-rays were examined and performed. No signs of osteoarthritis were found. Polymorphisms of MTNRK C677T and emoz T786C genes were determined in blood serum. The content of oxyproline, homocysteine, SRP was determined by immunoenzymatic method. A homozygous carrier of 677-Т1 and 786-СС was established, the levels of oxyproline - 32 μmol/l, homocysteine - 36 μmol/l, SRP - 17 mg/l.

The development of osteoarthritis was diagnosed. After 11 months, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphisms of the genes methylenetetrahydrofolate reductase (MTNEK C677T), nitric oxide synthase (EMO T786C), the content of oxyproline, homocysteine, C-reactive protein (CRP) are additionally determined ) and with homozygous carrier 677-177, 786-SS and levels of oxyproline 215 μmol/l, homocysteine 220 μmol/l, SRP »b mg/l predict the development of osteoarthritis.